The U.S. student loan crisis has evolved from a simmering economic concern into a full-blown structural challenge, reshaping the financial lives of millions and recalibrating the risks and opportunities for investors. Over the past two years, the end of pandemic-era repayment pauses, the expiration of delinquency reporting moratoriums, and the passage of the One Big Beautiful Bill Act (OBBB) in 2025 have created a volatile landscape. For young borrowers, the stakes are particularly high: 31% of those with payments due in early 2025 were 90+ days delinquent, with 1.8 million projected to default by July 2025 alone. For investors, the question is no longer whether student debt will impact markets, but how to navigate the turbulence…

Renovaro Inc. specializes in cancer diagnostics and therapeutics powered by artificial intelligence (AI). The Company operates through two subsidiaries: Renovaro Biosciences, Inc. (Renovaro Biosciences) and Renovaro Cube. Renovaro Biosciences is a biotechnology company intending to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections. Renovaro Cube is an AI-driven healthcare technology company focusing on the earliest possible detection of cancer and its recurrence. Renovaro Cube has…